These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 11054505)

  • 1. Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 levels in essential hypertension. Relationship to left ventricular mass and anti-hypertensive therapy.
    Li-Saw-Hee FL; Edmunds E; Blann AD; Beevers DG; Lip GY
    Int J Cardiol; 2000 Aug; 75(1):43-7. PubMed ID: 11054505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9 levels in patients with hypertension Relationship to tissue Doppler indices of diastolic relaxation.
    Tayebjee MH; Nadar SK; MacFadyen RJ; Lip GY
    Am J Hypertens; 2004 Sep; 17(9):770-4. PubMed ID: 15363818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abnormalities of the extracellular degradation of collagen type I in essential hypertension.
    Laviades C; Varo N; Fernández J; Mayor G; Gil MJ; Monreal I; Díez J
    Circulation; 1998 Aug; 98(6):535-40. PubMed ID: 9714110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum levels of MMP-9 and TIMP-1 in primary hypertension and effect of antihypertensive treatment.
    Onal IK; Altun B; Onal ED; Kirkpantur A; Gul Oz S; Turgan C
    Eur J Intern Med; 2009 Jul; 20(4):369-72. PubMed ID: 19524176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
    Tayebjee MH; Nadar S; Blann AD; Gareth Beevers D; MacFadyen RJ; Lip GY
    Am J Hypertens; 2004 Sep; 17(9):764-9. PubMed ID: 15363817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered matrix metalloproteinase 9 and tissue inhibitor of metalloproteinases 1 levels in children with primary hypertension.
    Niemirska A; Litwin M; Trojanek J; Gackowska L; Kubiszewska I; Wierzbicka A; Kułaga Z; Michałkiewicz J
    J Hypertens; 2016 Sep; 34(9):1815-22. PubMed ID: 27379542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effects of renin-angiotensin system blockers on left ventricular hypertrophy and biochemical markers of collagen balance in patients with hypertensive hypertrophy].
    Ovchinnikov AG; Serbul VM; Ageev FT
    Ter Arkh; 2009; 81(5):64-71. PubMed ID: 19537590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
    Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR
    Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effects of benidipine hydrochloride on severe left ventricular hypertrophy and collagen metabolism in patients with essential hypertension.
    Hirono O; Fatema K; Nitobe J; Takeishi Y; Kaneko K; Shiga R; Kubota I
    J Cardiol; 2002 Apr; 39(4):195-204. PubMed ID: 11977767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of the metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system on large arterial stiffness in patients with essential hypertension.
    Tan J; Hua Q; Xing X; Wen J; Liu R; Yang Z
    Hypertens Res; 2007 Oct; 30(10):959-63. PubMed ID: 18049028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of MMP-2 and MMP-9 in resistance to drug therapy in patients with resistant hypertension.
    Lacerda L; Faria AP; Fontana V; Moreno H; Sandrim V
    Arq Bras Cardiol; 2015 Aug; 105(2):168-75. PubMed ID: 26039662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of perindopril on elastic and structural properties of large arteries in essential hypertension.
    Lacourcière Y; Béliveau R; Conter HS; Burgess ED; Lepage S; Pesant Y; Spence JD; Asmar R; Carrière S; Plante GE;
    Can J Cardiol; 2004 Jun; 20(8):795-9. PubMed ID: 15229761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic AT(1) blockade stimulates extracellular collagen type I degradation and reverses myocardial fibrosis in spontaneously hypertensive rats.
    Varo N; Iraburu MJ; Varela M; López B; Etayo JC; Díez J
    Hypertension; 2000 Jun; 35(6):1197-202. PubMed ID: 10856263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension.
    Derosa G; D'Angelo A; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo S; Montagna L; Gravina A; Ferrari I; Galli S; Paniga S; Tinelli C; Cicero AF
    Endothelium; 2006; 13(3):227-31. PubMed ID: 16840178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases-1 and -2 levels in gestational hypertension.
    Tayebjee MH; Karalis I; Nadar SK; Beevers DG; MacFadyen RJ; Lip GY
    Am J Hypertens; 2005 Mar; 18(3):325-9. PubMed ID: 15797648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Collagen metabolism in extracellular matrix may be involved in arterial stiffness in older hypertensive patients with left ventricular hypertrophy.
    Ishikawa J; Kario K; Matsui Y; Shibasaki S; Morinari M; Kaneda R; Hoshide S; Eguchi K; Hojo Y; Shimada K
    Hypertens Res; 2005 Dec; 28(12):995-1001. PubMed ID: 16671339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction in left ventricular hypertrophy in hypertensive patients treated with enalapril, losartan or the combination of enalapril and losartan.
    Avanza AC; El Aouar LM; Mill JG
    Arq Bras Cardiol; 2000 Feb; 74(2):103-17. PubMed ID: 10904284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Ventricular remodeling and matrix metalloproteinase-1 and its tissue inhibitor of metalloproteinase-1 in serum in third trimester of pregnant women with cardiac disease.].
    Zhang ZL; Lin JH; Tao RQ
    Zhonghua Fu Chan Ke Za Zhi; 2009 Oct; 44(10):731-5. PubMed ID: 20078957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crosstalk between obesity and MMP-9 in cardiac remodelling -a cross-sectional study in apparent treatment-resistant hypertension.
    Ritter AM; de Faria AP; Barbaro N; Sabbatini AR; Corrêa NB; Brunelli V; Amorim R; Modolo R; Moreno H
    Blood Press; 2017 Apr; 26(2):122-129. PubMed ID: 27825280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relations of serum MMP-9 and TIMP-1 levels to left ventricular measures and cardiovascular risk factors: a population-based study.
    Hansson J; Lind L; Hulthe J; Sundström J
    Eur J Cardiovasc Prev Rehabil; 2009 Jun; 16(3):297-303. PubMed ID: 19387352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.